Transforming

Colorectal
Cancer
Screening

We are developing a non-invasive stool test for early detection of colon polyps and colorectal cancer based on an advanced interrogation of the human gut microbiome.

Preventing Cancer

We are focused on developing a non-invasive microbiome test for earlier and more accurate detection of colon polyps and colorectal cancer

Healthy Microbiome

Metabiomics is developing a pipeline of services for characterizing gut microbiome health and disease

MultiTag™ Sequencing

Our patented MultiTag™ DNA sequencing technology enables breakthrough next-generation sequencing and microbiome assays

About Us

Metabiomics is an early stage molecular diagnostics company

We are developing in-vitro diagnostics, screening tests, and health assays that leverage breakthroughs in next-generation DNA sequencing, computational systems biology, and human microbiome sciences.

Learn More

Latest News

FDA Grants Breakthrough Designation to the Prescient Metabiomics LifeKit® Prevent Test for the Early Detection of Colon Polyps and Colon Cancer

CARLSBAD, Calif., Sept. 4, 2019 /PRNewswire/ -- Prescient Metabiomics, a privately held company and a subsidiary of Prescient Medicine...

Prescient Medicine and Metabiomics Partner to Develop New Gastrointestinal Health Tests to Detect Polyps, Prevent Colon Cancer

Innovative new microbiome GI health solutions battle colon cancer and gastrointestinal disease Chicago, Sept. 18, 2018 – Prescient Medicine...

Metabiomics Featured in BiopharmaDIVE

In a recent article by Suzanne Elvidge, published in BiopharmaDIVE, Metabiomics was highlighted as a clinical development leader that is exploring...

Clinical Research

Metabiomics conducts microbiome systems biology, molecular diagnostics, and gastroenterology clinical research in collaboration with leading medical institutions and strategic partners across North America, Europe, and Asia. Please contact us directly to explore strategic alliance, collaboration, and technology licensing opportunities.

Partners

Contact Us

If you are interested in learning more about how Metabiomics is working to change the colon cancer screening paradigm, we would love to hear from you.